PharmaKure granted MHRA Clinical Trial Authorisation (CTA) for PK051 for the treatment of mild cognitive impairment due to Alzheimer’s Disease

Clinical Trial Authorisation application granted for combined drug PK051 targeting amyloid deposits associated with Alzheimer’s Disease.

Here are the cancer drugs Pfizer thinks could reignite investors’ interest

Pfizer spent more than four hours Thursday laying out its oncology program to investors. But the company also spent some time talking about the effects

March 1, 2024

Oregon Psilocybin: State of the State (2023)

It’s hard to believe that we are wrapping up the first year of the Oregon Psilocybin Services (OPS) program. Final rules were released at this

December 22, 2023

Frustrated telehealth providers say their businesses face ‘doom and gloom’

Telehealth providers treating opioid use disorder, ADHD, and women’s health issues say the sector is in a state of frustration and chaos as the pandemic-era

October 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.